Skip to main content
Top
Published in: Clinical Rheumatology 11/2019

01-11-2019 | Gout | Clinical Image

Monstrous gout devastating hands and feet

Authors: Mihaela C. Micu, Bombonica G. Dogaru

Published in: Clinical Rheumatology | Issue 11/2019

Login to get access

Excerpt

A 58-year-old man with onset of gout 8 years ago was admitted due to poor clinical conditions. He was treated with allopurinol 300 mg/day, but the dosage was not adjusted to the level of persistent uricemia (11 mg/dl). In this scenario, our patient experienced recurrent polyarticular gouty attacks despite being adherent to the prescribed therapy. Gigantic tophi (Fig. 1a, b), walking difficulties and feet ulcers due to spontaneous evacuation of a tophus were clinically evident. Hands and feet X-ray showed multiple destructive bone erosions due to large tophaceous depositions (Fig. 1c, d). Musculoskeletal ultrasound (MSUS) identified the presence of double contour sign (DCS, arrow) in the metacarpophalangeal joint and active synovitis in the joints of hands and feet (Fig. 1e, f, *). Monosodium urate (MSU) crystals were detected in the knee fluid as well as in the ulcerated tophaceous deposits. According to EULAR recommendations, colchicine 1 mg/day, NSAIDs, omeprazole 20 mg/day and urate lowering therapy with allopurinol adjusted to uric acid levels (600 mg/day) were prescribed. Knee fluid aspiration and intra-articular long-acting corticosteroid injection (Betamethasone) were performed [1]. Other laboratory analyses, renal/cardiac function and systemic blood pressure were normal. No kidney stones were detected. In the following two months, uric acid levels were significantly lowered (5.7 mg/dl). Febuxostat was identified as a potential future alternative therapy in case high dosage intolerance/side effects to allopurinol would appear. Follow-up visits in the next 18 months did not identify new joint/periarticular attacks. The ulcers showed a trend toward resolution but did not reach complete healing. Less walking difficulties were recorded mainly due to knee joint pain reduction.
Literature
1.
go back to reference Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29–42. https://doi.org/10.1136/annrheumdis-2016-209707 CrossRefPubMed Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29–42. https://​doi.​org/​10.​1136/​annrheumdis-2016-209707 CrossRefPubMed
2.
go back to reference Fodor D, Nestorova R, Vlad V, Micu M (2014) The place of musculoskeletal ultrasonography in gout diagnosis. Med Ultrason 16(4):336–344PubMed Fodor D, Nestorova R, Vlad V, Micu M (2014) The place of musculoskeletal ultrasonography in gout diagnosis. Med Ultrason 16(4):336–344PubMed
3.
go back to reference Gutierrez M, Smith W, Thiele R, Keen H, Kaeley G, Naredo E, Iagnocco A, Bruyn G, Balint P, Filippucci E, Mandl P, Kane D, Pineda C, Delle Sedie A, Hammer HB, de Miguel E, D'Agostino MA, Terslev L (2014) Defining elementary ultrasound lesions in gout. Preliminary results of Delphi consensus and web-exercise reliability. Ann Rheum Dis 73(Suppl2) Gutierrez M, Smith W, Thiele R, Keen H, Kaeley G, Naredo E, Iagnocco A, Bruyn G, Balint P, Filippucci E, Mandl P, Kane D, Pineda C, Delle Sedie A, Hammer HB, de Miguel E, D'Agostino MA, Terslev L (2014) Defining elementary ultrasound lesions in gout. Preliminary results of Delphi consensus and web-exercise reliability. Ann Rheum Dis 73(Suppl2)
4.
go back to reference Filippucci E, Riveros MG, Georgescu D, Salaffi F, Grassi W (2009) Hyaline cartilage in- volvement in patients with gout and calcium pyrophosphate deposition disease. An ultra- sound study. Osteoarthr Cartil 17:178–181CrossRef Filippucci E, Riveros MG, Georgescu D, Salaffi F, Grassi W (2009) Hyaline cartilage in- volvement in patients with gout and calcium pyrophosphate deposition disease. An ultra- sound study. Osteoarthr Cartil 17:178–181CrossRef
5.
go back to reference Neogi T, Jansen TL, Dalbeth N et al (2015) 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 67:2557–2568CrossRef Neogi T, Jansen TL, Dalbeth N et al (2015) 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 67:2557–2568CrossRef
6.
go back to reference Lee HY, Song GG (2018) Diagnostic accuracy of ultrasound in patients with gout: a meta-analysis Diagnostic value of US in patients with gout. Semin Arthritis Rheum 47(5):703–709CrossRef Lee HY, Song GG (2018) Diagnostic accuracy of ultrasound in patients with gout: a meta-analysis Diagnostic value of US in patients with gout. Semin Arthritis Rheum 47(5):703–709CrossRef
Metadata
Title
Monstrous gout devastating hands and feet
Authors
Mihaela C. Micu
Bombonica G. Dogaru
Publication date
01-11-2019
Publisher
Springer London
Keywords
Gout
Allopurinol
Published in
Clinical Rheumatology / Issue 11/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04764-2

Other articles of this Issue 11/2019

Clinical Rheumatology 11/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.